 Sonnet BioTherapeutics Holdings Inc NASDAQ: SONN stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 represents Sonnets second bispecific compound integrating Interleukin 12 IL-12 with the Companys Fully Human Albumin Binding FHAB platform. 